Evidence map›Paper›PMID 37071408›Full record

ArticleVector borne and zoonotic diseases (Larchmont, N.Y.)2023

Estimated Number of Symptomatic Lyme Borreliosis Cases in Adults in Finland in 2021 Using Seroprevalence Data to Adjust the Number of Surveillance-Reported Cases: A General Framework for Accounting for Underascertainment by Public Health Surveillance.

Julia Olsen, Frederick J Angulo, Andreas Pilz, Kate Halsby, Patrick Kelly, Juha Turunen, Heidi Åhman, James Stark, Luis Jodar

Open access · hybridAbstract read
In one paragraph

Article in Vector borne and zoonotic diseases (Larchmont, N.Y.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.8field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 3 countries.

Julia OlsenVaccines Medical Development & Scientific/Clinical Affairs, Pfizer, Inc., Collegeville, Pennsylvania, USA.
Frederick J AnguloVaccines Medical Development & Scientific/Clinical Affairs, Pfizer, Inc., Collegeville, Pennsylvania, USA.
Andreas PilzVaccines, Pfizer Corporation Austria, Vienna, Austria.
Kate HalsbyVaccines Medical Development & Scientific/Clinical Affairs, Pfizer, Inc., Collegeville, Pennsylvania, USA.
Patrick KellyVaccines Medical Development & Scientific/Clinical Affairs, Pfizer, Inc., Collegeville, Pennsylvania, USA.
Juha TurunenVaccines, Pfizer Oy Finland, Helsinki, Finland.
Heidi ÅhmanVaccines, Pfizer Oy Finland, Helsinki, Finland.
James StarkVaccines Medical Development & Scientific/Clinical Affairs, Pfizer, Inc., Collegeville, Pennsylvania, USA.
Luis JodarVaccines Medical Development & Scientific/Clinical Affairs, Pfizer, Inc., Collegeville, Pennsylvania, USA.
Pfizer (United States) · USVaisala (Finland) · FIPfizer (Austria) · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Borrelia burgdorferiLyme DiseaseAnimalsFinlandPublic Health SurveillanceSeroepidemiologic StudiesFinlandincidenceLyme borreliosisseroprevalencesurveillancetick-borne disease

Identifiers

PMID37071408
PMCPMC10122260
OpenAlexW4366238190

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.